Contrary to survivor-bias stories of long grinds to PMF, most successful companies get early signals from the market. If you're not getting informative feedback after two years, it might be time to reset the company's foundation, co-founders, or market focus.

The 'never give up' mantra is misleading. Successful founders readily abandon failed products and even entire startups. Their unwavering persistence is not tied to a specific idea, but to the meta-goal of finding product-market fit itself, no matter how many attempts it takes.

A visionary founder must be willing to shelve their ultimate, long-term product vision if the market isn't ready. The pragmatic approach is to pivot to an immediate, tangible customer problem. This builds a foundational business and necessary ecosystem trust, paving the way to realize the grander vision in the future.

The path for biotech entrepreneurs is a long slog requiring immense conviction. Success ("liftoff") isn't just a clinical trial result, but achieving self-sustaining profitability and growth. This high bar means founders may need to persevere through years of market indifference and financing challenges.

Founders often quit for the wrong reason: struggling to schedule meetings, which is merely a lack of data. The true signal to pivot or quit is when you've successfully engaged potential customers who have clear demand (pull) and they still explicitly reject your solution after multiple iterations.

Pursuing a genuinely non-obvious idea feels risky, not just uncertain. This feeling of danger—the fear of wasting years on a potential failure—is often a signal that you're working on something truly contrarian and valuable, as it deters others.

A key pattern among founders who fail is a refusal to accept unmovable realities, such as market dynamics. Instead of adapting, they try to change fundamental truths. Successful founders, in contrast, are truth-seekers who figure out how to work with or around constraints.

Founders must balance scientific conviction with market feedback. Kulkarni shares that his team abandoned pursuing certain indications that, while scientifically sound, failed to gain investor traction. This shows the critical need to pivot based on market signals, not just internal belief, to ensure continued funding and support.

When considering an exit, the primary risk isn't financial; it's the founder's time locked in a stagnating company. Spending productive years on a venture that's not working—even if well-funded—prevents a talented founder from pursuing the next big thing during a period of rapid technological change.